New Data on Endeavor Stent’s Long-Term Safety and Efficacy to Be Featured at Interventional Cardiology Congress

Medtronic, Inc. (NYSE: MDT), today announced planned highlights of new data presentations scheduled for the 2009 PCR meeting that feature the company’s cardiovascular innovations. From late breaking clinical trials, extensive new data on the Endeavor^® Drug-Eluting Stent (DES) will be presented, which shows unprecedented long-term efficacy for a DES.

Also featured are new data on Medtronic’s CoreValve^® transfemoral and subclavian aortic valve system. Medtronic also anticipates that PCR 2009 will coincide with the 4,000^th successful CoreValve implant.

Important data on the long-term efficacy and durable safety of the Endeavor DES will be presented in the following late-breaking clinical trial sessions:

Tuesday, May 19

• ENDEAVOR II and ENDEAVOR Pooled five-year data by Dr. D. Kandzari

Thursday , May 21

• DATE Registry on early discontinuation of antiplatelet therapy by Dr. H. Gwon.

Additional data related to Medtronic’s cardiovascular medical technologies will also be released in the following oral and poster contributions starting Tuesday, May 19:

• E-Five one-year ACS subset data by Prof. M. Rothman
• Medtronic CoreValve subclavian transcatheter aortic valve replacement by
  Dr. Jean-Claude Laborde
• E-Five one- and two-year data by Prof. I. Meredith

In addition, Medtronic will feature highlights of its current and future cardiovascular innovations at PCR (booth numbers D04 and F09). PCR takes place in Barcelona, Spain, May 19–22.

ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

Note: The Medtronic CoreValve System is not currently available for sale or clinical trials in the United States.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.